Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Minireview: Signal bias, allosterism, and polymorphic variation at the GLP-1R: implications for drug discovery.

Molecular endocrinology (Baltimore, Md.) - 1 Aug 2013

Koole Cassandra, Savage Emilia E, Christopoulos Arthur, Miller Laurence J, Sexton Patrick M, Wootten Denise

Abstract excerpt

The glucagon-like peptide-1 receptor (GLP-1R) controls the physiological responses to the incretin hormone glucagon-like peptide-1 and is a major therapeutic target for the treatment of type 2 diabetes, owing to the broad range of effects that are mediated upon its activation. These include the promotion of glucose-dependent insulin secretion, increased insulin biosynthesis, preservation of β-cell mass, improved...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Allosteric Regulation
Share to Drug Discovery

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glucagon-Like Peptide 1

Share to Glucagon-Like Peptide-1 Receptor

Share to Glucose

Share to Insulin

Share to Insulin Secretion

Share to Receptors, Glucagon

Source

Open in PubMed Open full text

Identifiers

PMID: 23864649
DOI: 10.1210/me.2013-1116
PMCID: PMC3725346

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Minireview: Signal bias, allosterism, and polymorphic variation at the GLP-1R: implications for drug discovery.PMID 23864649Read ↗

Biased agonism and polymorphic variation at the GLP-1 receptor: Implications for the development of personalised therapeuticsSemantic proximity Read ↗

Genetic variations in GLP-1R: Impact on diabetes and obesity therapeutics.Semantic proximity Read ↗

The GLP-1R as a model for understanding and exploiting biased agonism in next-generation medicinesSemantic proximity Read ↗

Differential impact of amino acid substitutions on critical residues of the human glucagon-like peptide-1 receptor involved in peptide activity and small-molecule allostery.Semantic proximity Read ↗

Global glucagon-like peptide-2 receptor activation linked to increased obesity risk in the UK Biobank.Semantic proximity Read ↗

Human GLP1R variants affecting GLP1R cell surface expression contribute to impaired glucose control and increased adipositySemantic proximity Read ↗

Ligand-independent modulation of GIPR signaling by splice variantsSemantic proximity Read ↗

A mini review on glucagon-like peptide-1 receptor agonists and its role in blood pressure regulationSemantic proximity Read ↗

<i>In vivo</i> functional profiling and structural characterisation of the human <i>Glp1r</i> A316T variantSemantic proximity Read ↗

Pharmacogenomics of GLP-1 Receptor Agonists: A genome wide analysis of observational data and large randomized controlled trialsSemantic proximity Read ↗

Naturally occurring mutations in G protein-coupled receptors associated with obesity and type 2 diabetes mellitus.Semantic proximity Read ↗

Pharmacogenomics of GLP-1 Receptor Agonists: Precision Medicine in the Age of Ozempic and MounjaroSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.